Form 8-K

8-K — Bausch & Lomb Corp

Accession: 0000950103-26-011979

Filed: 2026-08-06

Period: 2026-08-05

CIK: 0001860742

SIC: 3851 (OPHTHALMIC GOODS)

Item: Entry into a Material Definitive Agreement

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — dp251415_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (dp251415_ex9901.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: dp251415_8k.htm · Sequence: 1

false

0001860742

Bausch & Lomb Corp

0001860742

2026-08-05

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 8-K

____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 5, 2026

Date of Report (Date of the earliest event

reported)

____________________________

Bausch + Lomb Corporation

(Exact Name of Registrant as Specified in Its

Charter)

____________________________

Canada

001-41380

98-1613662

(State or Other Jurisdiction of

Incorporation or Organization)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

520 Applewood Crescent

Vaughan, Ontario

Canada L4K 4B4

(Address of Principal Executive Offices) (Zip

Code)

(905) 695-7700

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed since

last report)

____________________________

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to

Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, No Par Value

BLCO

New York Stock Exchange

Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 1.01

Entry into a Material Definitive Agreement.

The information set forth below under Item 5.02

with respect to the Ross Agreement (as defined below) is hereby incorporated by reference into this Item 1.01.

Item 5.02 Departure of Directors or

Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 6, 2026, Bausch + Lomb Corporation (the “Company”)

announced the appointment of Thomas J. Appio, Robert Chersi, Laurence Paul, M.D. and Barbara Trebbi to its board of directors (the “Board”),

effective August 5, 2026, to fill the vacancies created by the resignations of Steven H. Collis, Karen L. Ling, Thomas W. Ross, Sr. and

Andrew C. von Eschenbach, M.D. (collectively, the “Resigning Directors”) from the Board, effective August 5, 2026 .

The Board has determined that each of Mr. Chersi, Dr. Paul and Ms.

Trebbi is independent in accordance with applicable New York Stock Exchange and Toronto Stock Exchange rules and applicable Canadian securities

laws. At the time of this filing, the Board has not yet determined the committee(s), if any, to which Mr. Appio, Mr. Chersi, Dr. Paul

and Ms. Trebbi will be appointed, nor has the Board determined who will serve as lead independent director.

Mr. Chersi, Dr. Paul and Ms. Trebbi will receive compensation in accordance

with the Company’s Non-Employee Directors Compensation Policy (as in effect from time to time), as described in the Company’s

2026 Annual Proxy Statement, and each of Mr. Appio, Mr. Chersi, Dr. Paul and Ms. Trebbi have entered into the Company’s standard

form of director indemnification agreement.

The new appointments were made at the request of Bausch Health Companies

Inc. (“BHC”), the Company’s controlling shareholder. Mr. Appio is the Chief Executive Officer of BHC. The information

required by Item 404(a) of Regulation S-K for Mr. Appio is included in the Company’s Definitive Proxy Statement related to the Company’s

2026 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 10, 2026, which information is incorporated

herein by reference. Other than that, there are no arrangements or understandings between any of Mr. Appio, Mr. Chersi, Dr. Paul and Ms.

Trebbi and any other person pursuant to which any of such individuals was selected as a director.

The resignations of the Resigning Directors were not due to any disagreement

or dispute with the Company. In connection with their resignation and entry into a general mutual release of certain claims, the Company

has agreed to pay the Resigning Directors prorated cash compensation for their service and accelerated the vesting, in full, of the outstanding

and unvested restricted stock unit awards received by the Resigning Directors as part of their 2026 annual grant. In addition, the Company

and Mr. Ross have entered into a consulting agreement, pursuant to which Mr. Ross has agreed to provide certain consulting and advisory

services to the Company and the Board for a period of one (1) year, unless terminated earlier (the “Ross Agreement”). Pursuant

to the Ross Agreement, Mr. Ross will be entitled to a consulting fee of $400,000, payable in four quarterly installments of $100,000.

The Ross Agreement may be terminated by either party on 30 days’ prior written notice or by the Company immediately for cause.

The foregoing is a summary description of the terms of the Ross Agreement

and is qualified in its entirety by the full text of the Ross Agreement, a copy of which will be filed with the Company’s Quarterly

Report on Form 10-Q for the quarter ending September 30, 2026.

Item 8.01 Other Events

On August 6, 2026, the Company issued a press release announcing the

update to the Board along with certain financial information for the quarter ended June 30, 2026. A copy of the press release is attached

as Exhibit 99.1 to this report.

The information in this Item 8.01, including Exhibit 99.1, is being

furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,

or otherwise subject to the liabilities of that Section. The information in this Item 8.01 and Exhibit 99.1 shall not be incorporated

by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press Release, dated August 6, 2026.

104

Cover Page Interactive Data File (formatted as Inline XBRL).

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BAUSCH + LOMB CORPORATION

By:

/s/ A. Robert D. Bailey

Name:

A. Robert D. Bailey

Title:

Executive Vice President and Chief Legal Officer

Date: August 6, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: dp251415_ex9901.htm · Sequence: 2

Exhibit 99.1

Bausch + Lomb Announces Board of Directors Update,

Reaffirms Guidance

VAUGHAN, Ontario, Aug. 6, 2026 – Bausch + Lomb Corporation (NYSE/TSX:

BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board

of Directors.

At the request of Bausch Health Companies Inc. (“Bausch Health”),

which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or

indirectly through its wholly owned subsidiaries, approximately 87% of the company’s outstanding common shares, the Bausch + Lomb

Board has appointed four new directors, effective Aug. 5, 2026:

· Thomas J. Appio, CEO, Bausch Health

· Robert Chersi, founder of Chersi Services LLC, executive director and

a professor at Pace University’s Center for Governance, Reporting & Regulation and a seasoned director

· Laurence Paul, MD, co-founder and managing principal of Laurel Crown

Partners, LLC, president of The Louis Berkman Company, minority owner of the Pittsburgh Steelers and a director of Crew Knitwear, Vereco

and Ampco-Pittsburgh Corporation

· Barbara Trebbi, president and co-CEO of Landry Trebbi Investment Corp.,

president of BXT Corp. and director of Acadian Asset Management Inc.

The new directors replace Steven Collis, Karen Ling, Thomas Ross and

Andrew von Eschenbach, MD, each of whom has tendered their resignation to facilitate the new appointments; none of the resignations were

the result of any disagreement with the company.

“We welcome our new directors and appreciate the service and contributions

of those departing the Board,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Over the past several years, we’ve

been very transparent about our strategy and the work required to build a stronger Bausch + Lomb. Today, we have exceptional talent across

the company, momentum throughout our businesses and the strongest pipeline we’ve had in years. Our second-quarter performance reflects

what this team has methodically built and the disciplined execution behind it, and our focus remains on executing our strategy and delivering

long-term value.”

Bausch + Lomb delivered second-quarter revenue of $1.394 billion, an

increase of 9% on a reported basis and 8% on a constant currency basis1 compared with the second quarter of 2025. Growth

was broad-based across all segments, with double-digit revenue growth in Surgical and Pharmaceuticals, while significant margin expansion

led to improved profitability. Net cash provided by operating activities (also referred to as cash flow from operations) increased more

than four times, from $32 million in the first quarter to $153 million in the second. Adjusted cash flow from operations (non-GAAP)1

more than tripled, from $45 million in the first quarter to $161 million in the second.2

This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the

“Non-GAAP Information” section of this news release. Please also refer to tables at the end of this news release for a reconciliation

of this and other non-GAAP measures to the most directly comparable GAAP measure.

Adjusted cash flow from operations (non-GAAP) is net cash provided by operating activities (also referred to as Cash flow from operations),

its most closely associated GAAP measure, less (i) Business Transformation payments of $7 million in the first quarter of 2026 and $3

million in the second quarter of 2026, (ii) financing payments related to the modification of the debt of $6 million in the first quarter

of 2026 and (iii) payments of legacy legal settlements of $5 million in the second quarter of 2026.

The company is also advancing a diversified pipeline across dry eye

disease, surgical technologies, consumer eye health, contact lenses, retinal diseases and emerging areas including AI and computational

biology. This breadth is designed to support a sustained cadence of innovation and address important structural trends in eye health,

including aging populations, rising childhood myopia and the growing prevalence of dry eye and retinal disease.

Reaffirming 2026 Guidance3

Bausch + Lomb reaffirms the full-year 2026 guidance it raised on July

29, 2026, including revenue of $5.440 billion to $5.540 billion and Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1

of $1.025 billion to $1.075 billion.4

###

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved

with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has

never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning

bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and

connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Forward-looking Statements

This news release contains forward-looking information and statements

within the meaning of applicable securities laws (collectively, “forward-looking statements”), which may generally be identified

by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,”

“projects,” “predicts,” “forecasts,” “should,” “could,” “would,”

“may,” “might,” “will,” “strive,” “believes,” “estimates,” “potential,”

“target,” “guidance,” “outlook,” or “continue” and positive and negative variations or

similar expressions and phrases or statements that certain actions, events or results may, could, should or will be achieved, received

or taken, or will occur or result, and similar such expressions also identify forward-looking information. Forward-looking statements

include statements regarding Bausch + Lomb’s future prospects and performance, including the company’s 2026 full-year guidance,

and the company’s pipeline. These forward-looking statements, including the company’s full-year guidance, are based upon the

current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations

and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements

are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking

statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s

filings with the U.S. Securities and Exchange Commission (“SEC”) and the Canadian Securities Administrators (the “CSA”)

(including the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2025 (which was filed with the SEC and CSA on Feb.

18, 2026) and its most recent quarterly filings), which factors are incorporated herein by reference. In addition, certain material factors

and assumptions have been applied in making these forward-looking statements, including, without limitation, the assumption that the risks

and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking

statements. In addition, management has also made certain assumptions regarding our 2026 full-year guidance with respect to expectations

regarding base performance growth, business performance, currency impact, inflation, the company's ability to offset the impact of tariffs

in 2026 (based on the current tariff policy and the actions the company is taking to manage these measures), expectations regarding adjusted

gross margin (non-GAAP), adjusted SG&A expense (non-GAAP) and the company’s ability to continue to manage such expense in the

manner anticipated, net interest expense (which will vary based on, among other things, interest rates and our indebtedness), adjusted

tax rate and full year capex and the anticipated timing and extent of the company’s R&D expense.

Other than with respect to GAAP revenue, the company only provides guidance on a non-GAAP basis. The company does not provide a reconciliation

of forward-looking Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) to GAAP net income (loss) attributable to Bausch + Lomb Corporation

due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts

may be material and, therefore, could result in the projected GAAP measure or ratio being materially different or less than the projected

non-GAAP measure or ratio. These statements represent forward-looking information and may represent a financial outlook, and actual results

may vary. Please see the risks and assumptions referred to in the Forward-looking Statements section of this news release.

The affirmed guidance in this news release is only effective as of the date given, August 6, 2026, and will not be updated or affirmed

unless and until the company publicly announces updated or affirmed guidance. Distribution or reference of this news release following

August 6, 2026, does not constitute the company reaffirming guidance. See the “Forward-looking Statements” section for further

information. This guidance does not take into consideration any changes in tariff policy, given the dynamic nature of the situation.

Readers are cautioned not to place undue reliance on any of these forward-looking

statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of

these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes,

unless required by law.

Non-GAAP Information

To supplement the financial measures prepared in accordance with U.S.

generally accepted accounting principles (GAAP), the company uses certain non-GAAP financial measures and ratios. Management uses these

non-GAAP measures and ratios as key metrics in the evaluation of the company’s performance and the consolidated financial results

and, in part, in the determination of cash bonuses for its executive officers. The company believes these non-GAAP measures and ratios

are useful to investors in their assessment of our operating performance and the valuation of the company. In addition, these non-GAAP

measures and ratios address questions the company routinely receives from analysts and investors, and in order to assure that all investors

have access to similar data, the company has determined that it is appropriate to make this data available to all investors.

These measures and ratios do not have any standardized meaning under

GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way

we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to similar non-GAAP

measures and ratios of other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead

to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as

analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior

to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historic non-GAAP financial measures and

ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the

tables below.

Specific Non-GAAP Measures

EBITDA, Adjusted EBITDA and Adjusted EBITDA excluding Acquired IPR&D EBITDA (non-GAAP) is Net income (loss) attributable to Bausch

+ Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest, income taxes, depreciation

and amortization. Adjusted EBITDA (non-GAAP) is EBITDA (non-GAAP) further adjusted for the items described below. Management believes

that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the company measures

the business internally and sets operational goals and incentives. In particular, the company believes that Adjusted EBITDA (non-GAAP)

focuses management on the company’s underlying operational results and business performance. As a result, the company uses Adjusted

EBITDA (non-GAAP) both to assess the actual financial performance of the company and to forecast future results as part of its guidance.

Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended

to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In

addition, cash bonuses for the company’s executive officers and other key employees are based, in part, on the achievement of certain

Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) is Net income (loss) attributable to Bausch

+ Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest expense, net, (benefit from)

provision for income taxes, depreciation and amortization and further adjusted for the following items:

· Asset impairments: The company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets as such

amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures.

The company believes that the adjustments of these items correlate with the sustainability of the company’s operating performance.

Although the company excludes impairments of intangible assets from measuring the performance of the company and its business, the company

believes that it is important for investors to understand that intangible assets contribute to revenue generation.

· Restructuring, integration and transformation costs: The company has incurred restructuring costs as it implemented certain strategies,

which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture

of assets and businesses. With regard to infrastructure and operational improvements which the company has taken to improve efficiencies

in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly

between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the

completion of the Bausch + Lomb IPO, as the company prepares for post-separation operations, the company is launching certain transformation

initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation

initiatives arise outside of the ordinary course of continuing operations and, as is the case with the company’s restructuring efforts,

costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course

charges include third-party advisory costs, as well as certain compensation-related costs. Investors should understand that the outcome

of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The company believes

that the adjustments of these items provide supplemental information with regard to the sustainability of the company’s operating

performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide

useful supplemental information to investors.

· Acquisition-related costs and adjustments excluding amortization of intangible assets: The company has excluded the impact of acquisition-related

costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not

consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the company excludes the impact of

acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such

amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not

consistent and are significantly impacted by the timing and size of the company’s acquisitions, as well as the nature of the agreed-upon

consideration.

· Share-based compensation: The company excludes costs relating to share-based compensation. The company believes that the exclusion

of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation

expense can vary significantly based on the timing, size and nature of awards granted.

· Separation costs and separation-related costs: The company has excluded certain costs incurred in connection with activities taken

to: (i) separate the Bausch + Lomb business from the remainder of BHC and (ii) register the Bausch + Lomb business as an independent publicly

traded entity. Separation costs are incremental costs directly related to effectuating the separation of the Bausch + Lomb business from

the remainder of BHC and include, but are not limited to, legal, audit and advisory fees, talent acquisition costs and costs associated

with establishing a new Board of Directors and Audit Committee. Separation-related costs are incremental costs indirectly related to the

separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, IT infrastructure and software

licensing costs, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events

outside of the ordinary course of continuing operations, the company believes that the adjustments of these items provide supplemental

information with regard to the sustainability of the company’s operating performance, allow for a comparison of the financial results

to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

· Loss on extinguishment of debt: The company has excluded loss on extinguishment of debt as this represents a loss from refinancing

our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such amounts are not

consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market that

are not within management’s control.

· Other Non-GAAP adjustments: The company also excludes certain other amounts, including IT infrastructure investment, litigation and

other matters, gain/(loss) on sales of assets and certain other amounts that are the result of other, non-comparable events to measure

operating performance if and when present in the periods presented. These events arise outside of the ordinary course of continuing operations.

Given the unique nature of the matters relating to these costs, the company believes these items are not routine operating expenses. For

example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the company

believes the costs associated with legal settlements and judgments are not routine operating expenses. The company excluded these costs

as this event is outside of the ordinary course of continuing operations and is infrequent in nature. The company believes that the exclusion

of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the

company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand

that many of these costs could recur and that companies in our industry often face litigation.

Adjusted EBITDA excluding Acquired In-Process Research and Development

(IPR&D) (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude Acquired IPR&D. The IPR&D expenditures represent

costs directly resulting from business development transactions and not through the normal course of business. The company believes that

the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial

results of the company from period to period and, therefore, provides useful supplemental information to investors in assessing our performance.

However, investors should understand that the company may enter into additional business development transactions in the future and, as

a result, such Acquired IPR&D may recur in the future.

Constant Currency

Constant currency change or constant currency revenue growth is a change

in GAAP revenue (its most directly comparable GAAP financial measure) on a period-over-period basis adjusted for changes in foreign currency

exchange rates. The company uses Constant Currency revenue (non-GAAP) and Constant Currency revenue Growth (non-GAAP) to assess performance

of its reportable segments, and the company in total, without the impact of foreign currency exchange fluctuations. The company believes

that such measures are useful to investors as they provide a supplemental period-to-period comparison. Although changes in foreign currency

exchange rates are part of our business, they are not within management’s control. Changes in foreign currency exchange rates, however,

can mask positive or negative trends in the underlying business performance. Constant currency impact is determined by comparing current

period reported amounts adjusted to exclude currency impact, calculated using monthly average exchange rates from the prior comparable

period to the actual prior comparable period reported amounts.

Adjusted Cash Flows from Operations/Adjusted Cash used in Operations

Adjusted cash flows from operations (non-GAAP)/Adjusted Cash used in

Operations (non-GAAP) is Net Cash provided by Operating Activities (also referred to as Cash flow from operations/Cash used in operations

(loss)) (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance

proceeds, if any (ii) payments for separation costs, IPO costs, separation-related costs, and IPO-related costs (iii) payments for business

transformation costs and (iv) payments for financing fees related to the modification of debt, if any. Management believes that Adjusted

cash flows from operations (non-GAAP)/Adjusted Cash used in Operations (non-GAAP), along with the GAAP and non-GAAP measures used by management,

most appropriately reflect how the company measures the business internally. The company uses adjusted cash flows from operations (non-GAAP)/Adjusted

Cash used in Operations (non-GAAP) both to assess the actual financial performance of the company and to forecast future results as part

of its guidance. Management believes adjusted cash flows from operations (non-GAAP)/Adjusted Cash used by Operations (non-GAAP) is a useful

measure to evaluate current performance amounts. As these payments arise from events outside of the ordinary course of continuing operations

as discussed above, the company believes that the adjustments of these items provide supplemental information with regard to the sustainability

of the company’s cash from operations, allow for a comparison of the financial results to historical operations and forward-looking

guidance and, as a result, provide useful supplemental information to investors.

Media Contact:

T.J. Crawford

tj.crawford@bausch.com

(908) 705-2851

Investor Contact:

George Gadkowski

george.gadkowski@bausch.com

(877) 354-3705 (toll free)

FINANCIAL TABLE FOLLOWS

Bausch + Lomb Corporation

Table

Constant Currency Revenue (non-GAAP) and Constant Currency Revenue

Growth (non-GAAP)

For the Three Months Ended June 30, 2026 and 2025

(unaudited)

Calculation of Constant Currency Revenue for the Three Months Ended

June 30, 2026

June 30, 2025

Change in Revenue as Reported

Change in

Constant

Currency Revenue (Non-GAAP)(b)

(in millions)

Revenue

Reported

Changes

in Exchange Rates(a)

Constant Currency Revenue

(Non-GAAP)(b)

Revenue

Reported

Amount

Pct.

Amount

Pct.

Total revenues

$ 1,394

$ (12 )

$ 1,382

$ 1,278

$ 116

9 %

$ 104

8 %

(a) The impact for changes in foreign currency exchange rates is determined

as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported

revenues revalued using the monthly average currency exchange rates during the comparable prior period.

(b) To supplement the financial measures prepared in accordance with

GAAP, the Company uses certain non-GAAP financial measures and ratios. For additional information about the Company’s use of such

non-GAAP financial measures and ratios, refer to the “Non-GAAP Information” section in the body of the news release to which

these tables are attached. Constant currency revenue (non-GAAP) for the three months ended June 30, 2026 is calculated as revenue as reported

adjusted for the impact for changes in exchange rates. Change in constant currency revenue (non-GAAP) is calculated as the difference

between constant currency revenue for the current period and revenue as reported for the comparative period.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity File Number

001-41380

Entity Registrant Name

Bausch & Lomb Corp

Entity Central Index Key

0001860742

Entity Tax Identification Number

98-1613662

Entity Incorporation, State or Country Code

Entity Address, Address Line One

520 Applewood Crescent

Entity Address, City or Town

Vaughan

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

L4K 4B4

City Area Code

905

Local Phone Number

695-7700

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Shares, No Par Value

Trading Symbol

BLCO

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration